Page 7 of 10: studies 121 to 140 of 189, newest first. Back to the ketamine overview
Journal watch April 23, 2018 Joel Yager
Intravenous ketamine reduces symptoms of depression and suicidality for up to several weeks, but less is known about the non–FDA-approved intranasal
International Journal of Environmental Research and Public Health April 17, 2018 Carola Rong, Caroline Park, Joshua D. Rosenblat et al. 116 citations
OBJECTIVES: Extant evidence indicates that ketamine exerts rapid antidepressant effects in treatment-resistant depressive (TRD) symptoms as a part of major depressive disorder (MDD) and bipolar disorder (BD). The identification of depressed sub-populations that are more likely to benefit from ketamine treatment remains a priority. In keeping with this view, the present narrative review aims to...
American Journal of Psychiatry April 16, 2018 Carla M. Canuso, Jaskaran Singh, Maggie Fedgchin et al. 666 citations
OBJECTIVE: The authors compared the efficacy of standard-of-care treatment plus intranasal esketamine or placebo for rapid reduction of symptoms of major depression, including suicidality, among individuals at imminent suicide risk. METHOD: In a double-blind, multicenter, proof-of-concept study, 68 participants were randomly assigned to receive esketamine (84 mg) or placebo twice weekly for 4...
Frontiers in Behavioral Neuroscience April 16, 2018 André Schwertner, Maxciel Zortéa, Felipe Vasconcelos Torres et al. 48 citations
Ketamine is a non-competitive N-Methyl-D-Aspartate (NMDA) receptor antagonist whose effect in subanesthetic doses has been studied for chronic pain and mood disorders treatment. It has been proposed that ketamine could change the perception of nociceptive stimuli by modulating the cortical connectivity and altering the top-down mechanisms that control conscious pain perception. As this is a...
Journal of Affective Disorders April 15, 2018 Elizabeth D. Ballard, Julia S Yarrington, Cristan A Farmer et al.
Due to the heterogeneity of depressive symptoms-which can include depressed mood, anhedonia, negative cognitive biases, and altered activity levels-researchers often use a combination of depression rating scales to assess symptoms. This study sought to identify unidimensional constructs measured across rating scales for depression and to evaluate these constructs across clinical trials of a...
British Journal of Anaesthesia April 13, 2018 Phillip E. Vlisides, Tarik Bel‐bahar, Amanda Nelson et al. 117 citations
BackgroundDespite its designation as a 'dissociative anaesthetic,' the dissociative and psychoactive effects of ketamine remain incompletely understood. The goal of this study was to characterise the subjective experiences and accompanying EEG changes with subanaesthetic doses of ketamine.MethodsHigh-density EEG was recorded in 15 human volunteers before, during, and after subanaesthetic...
The International Journal of Neuropsychopharmacology April 10, 2018 Jessica R. Gilbert, Julia S Yarrington, Kathleen E. Wills et al. 58 citations
BACKGROUND: The glutamatergic modulator ketamine has rapid antidepressant effects in individuals with major depressive disorder and bipolar depression. Thus, modulating glutamatergic transmission may be critical to effectively treating depression, though the mechanisms by which this occurs are not fully understood. METHODS: This double-blind, crossover, placebo-controlled study analyzed data...
European Neuropsychopharmacology April 2018 Francesc Artigas, Pau Celada, Analia Bortolozzi
In the second part we focus on two treatment strategies that may overcome the main limitations of current antidepressant drugs. First, we review the experimental and clinical evidence supporting the use of glutamatergic drugs as fast-acting antidepressants. Secondly, we review the involvement of microRNAs (miRNAs) in the pathophysiology of major depressive disorder (MDD) and the use of small...
Journal of Psychopharmacology April 2018 Verònica Gálvez, Adrienne Li, Christina Huggins et al.
Ketamine research in depression has mostly used intravenous, weight-based approaches, which are difficult to translate clinically. Intranasal (IN) ketamine is a promising alternative but no controlled data has been published on the feasibility, safety and potential efficacy of repeated IN ketamine treatments. This randomised, double-blind, placebo-controlled pilot study compared a 4-week course...
Magnesium Research April 1, 2018 Natalia Górska, Wiesław Jerzy Cubała, Jakub Słupski et al. 8 citations
Depression is one of the major causes of disability worldwide. A proportion of adults with major depression fail to achieve remission with first-line treatment. Magnesium influences the neurotransmission involved in emotional processes, such as the serotonergic, noradrenergic, dopaminergic, GABAergic and glutamatergic systems. It has been reported that the mechanism of antidepressants' action...
Proceedings of the National Academy of Sciences March 27, 2018 Allie J Widman, Lori L McMahon
Low-dose ketamine, an open-channel N-methyl d-aspartate receptor (NMDAR) antagonist, mediates rapid antidepressant effects in humans that are mimicked in preclinical rodent models. Disinhibition of pyramidal cells via decreased output of fast-spiking GABAergic interneurons has been proposed as a key mechanism that triggers the antidepressant response. Unfortunately, to date, disinhibition has...
PLoS One March 22, 2018 B. Roth, Simon Gibbons, Warunya Arunotayanun et al. correction
[This corrects the article DOI: 10.1371/journal.pone.0059334.].
Biochimica et Biophysica Acta. Proteins and Proteomics March 18, 2018 Basant Pradhan, Ludmil Mitrev, Ruin Moaddell et al. 67 citations
Post-traumatic stress disorder (PTSD) is a chronic and debilitating condition that is often refractory to standard frontline antidepressant therapy. A promising new approach to PTSD therapy is administration of a single sub-anesthetic dose of (R,S)-ketamine (Ket). The treatment produces rapid and significant therapeutic response, which lasts for only 4-7 days. In one of our studies, the mean...
Neuroscience Letters March 16, 2018 Jeffrey Landrigan, Farah Shawaf, Zach Dwyer et al.
The efficacy of ketamine to alleviate depressive symptoms has promoted a wealth of research exploring alternate therapeutic targets for depression. Given the caveats of ketamine treatment taken together with the increasingly greater emphasis on combinatorial therapeutic approaches to depression, we sought to asses whether the hypothalamic "hunger hormone", ghrelin, would augment the effects of...
Molecular Psychiatry March 13, 2018 Panos Zanos, T. Gould 1,112 citations
Clinical studies have demonstrated that a single sub-anesthetic dose of the dissociative anesthetic ketamine induces rapid and sustained antidepressant actions. Although this finding has been met with enthusiasm, ketamine’s widespread use is limited by its abuse potential and dissociative properties. Recent preclinical research has focused on unraveling the molecular mechanisms underlying the...
Behavioural Pharmacology March 13, 2018 Rachel R. Horsley, Tomáš Páleníček, Jan Kolin et al. 52 citations
Short-term moderate doses of serotonergic and dissociative hallucinogens can be useful in the treatment of anxiety. Recently, a trend has developed for long-term intermittent 'microdosing' (usually one-tenth of a 'full' active dose), with reports of long-lasting relief from anxiety and related disorders; however, there is no scientific evidence for the efficacy of therapeutic microdosing nor to...
The Brown University Psychopharmacology Update March 9, 2018
Patients with treatment‐resistant depression who received intranasal esketamine as adjunctive therapy with an antidepressant experienced greater symptom improvement than patients receiving adjunctive placebo, a multiphase study with 67 participants has found. The antidepressant effect seen in the study was dose‐related, and adverse events led to study discontinuation in only a small number of...
Scientific Reports March 5, 2018 Kai Zhang, Yuko Fujita, Kenji Hashimoto
Since the metabolism of (R,S)-ketamine to (2R,6R)-hydroxynorketamine (HNK) is reported to be essential for ketamine's antidepressant effects, there is an increasing debate about antidepressant effects of (2R,6R)-HNK. Using pharmacokinetic and behavioral techniques, we investigated whether intracerebroventricular (i.c.v.) infusion of (R)-ketamine or (2R,6R)-HNK show antidepressant effects in a...
Molecular Psychiatry February 27, 2018 Allison C. Nugent, Elizabeth D. Ballard, T. Gould et al. 254 citations
Ketamine’s mechanism of action was assessed using gamma power from magnetoencephalography (MEG) as a proxy measure for homeostatic balance in 35 unmedicated subjects with major depressive disorder (MDD) and 25 healthy controls enrolled in a double-blind, placebo-controlled, randomized cross-over trial of 0.5 mg/kg ketamine. MDD subjects showed significant improvements in depressive symptoms,...
Biological Psychiatry February 23, 2018 Alessia Mastrodonato, Randy Martinez, Ina P. Pavlova et al.
BACKGROUND We previously reported that a single injection of ketamine prior to stress protects against the onset of depressive-like behavior and attenuates learned fear. However, the molecular pathways and brain circuits underlying ketamine-induced stress resilience are still largely unknown. METHODS Here, we tested if prophylactic ketamine administration altered neural activity in the...